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Each FLQ was bactericidal against SP 007, with LEV being the most bactericidal FLQ using either Smax or Lmax BI 
breakpoints. All the FLQs tested showed less kill against SP 303, as would be expected. Only LEV or MOX showed an Smax 
BI against this strain. However, with Lmax breakpoints, GRE was slightly more bactericidal than LEV and MOX was the 
most bactericidal. To conclude, of the FLQs tested, LEV or MOX should retain bactericidal activity against infections caused 
by FLQ-intermediate SP. However, none of the FLQs were bactericidal against the OFL-resistant SP 18 1 and therefore would 
not be expected to show bactericidal activity against infections caused by FLQ-resistant SI? 
23. Does appropriate antibiotic treatment influence outcome in 
community-acquired pneumonia (CAP)? 
M. NIEDERMAN, D. CHURCH, J. KAUFMANN AND M. SPRINGSKLEE 
Background: Community-acquired pneumonia (CAP) is a common cause of morbidity throughout the world with an 
estimated incidence of 12 cases per 1000 people per year. Mortality has been estimated by the WHO to be between 500 000 
and 1.4 million deaths per year. As such, it is a major cost to the health services of all countries and treatment should be as 
appropriate as possible. 
Objective: To compare the hospitalization and mortality rates in 4 multi-national trials in patients with CAP treated with 
either moxifloxacin (MXF) or comparitor (amoxicillin [AMOX] or clarithromycin [CLAR]). 
Methods: Pooled patient data were subjected to meta-analysis. The number of deaths in all our controlled CAP studies was 
determined by defining deaths as those that occurred within 30 days of the end of treatment. 
Results: Among 701 MXF-treated patients there were 4 deaths (0.57%) compared to 12 deaths among the 705 comparitor- 
treated patients (1.70%; P=O.O45). Thirty-nine of the 701 (5.6%) MXF-treated patients were hospitalized compared to 43 
(6.1%) comparitor-treated patients. 
Conclusions: Across four controlled clinical trials of CAP, the mortality rate for moxifloxacin-treated patients was significantly 
better than that for comparitor-treated patients. In addition, slightly more patients treated with the comparitor agents were 
hospitalized compared to those treated with moxifloxacin. 
24. More common microbiological agents responsible of acute exacerbation of 
COPD in a northern area of Italy 
M. PECIS, M. SCOZZAFAVA, A. CERAMINIELLO* AND F. MARCHESANI 
Department of Pneumology, *Microbiology Laboratory, Ospedale Maggiore, Lodi, Italy. 
There is not an universally accepted definition of acute exacerbation of COPD. A descriptive definition could be: “an acute, 
episodic deterioration superimposed on stable COPD with: increased dyspnoea, reduced daily performance, with or without 
changes in sputum volume and colour, coughing, or body temperature; and/or alteration in mental status” (Eur Respir Man, 
1998, 7,264). Many are the causes of acute exacerbation of COPD (AECB); in over half cases the ethiology is an infection of 
the tracheobronchial tree. 
The aim of the study is the detection of the more common microbiological agents responsible of AECB along a period of 
one year. 
From October 1998 to September 1999, 567 patients (80.3% males, 19.7% females) affected by respiratory diseases were 
admitted in our Department. AECB was diagnosed in 71 cases (12.5%, mean age 7222 yrs, 52 males and 19 females). In only 
7 patients the microbiological samples (smear or broncoscopy aspirated) were positive. The agents detected were: 5 Pseudo- 
monas Aer., 2 Streptococcus Pn., 2 Haemophilus InJuenzae, 2 St. Aureus, 1 Acrobacter Xyloxidans, 1 Serratia Marcescens, 1 
Enterobacter Aerogenes. 
Our hospital is active in a country area in southern Padana Plain (PO river area) with continental climate, mean temperature 
of 26/30” C in summer and g/10-12” C in winter; relative humidity is 70/80% in summer and 54/74% in winter. The most 
prevalence of AECB was observed in February-May period. This fact may be due to the climate variations. 
Pseudomonas Aer. is not usually described as the more common cause of infective AECB. Our data may be related to the 
age of the patients (elderly). 
